The pharmaceutical company GlaxoSmithKline (GSK) has announced a five-year collaboration with UC Berkeley and UCSF to establish the Laboratory for Genomics Research (LGR), where state-of-the-art CRISPR techniques will be used to advance the genomic research and rapidly accelerate new drug development.
“LGR is about building that space where creative science is partnered with the development of robust technology that will help develop tomorrow’s drugs. I think we’re going to be able to do science that none of us can even imagine today," said MCB & Chemistry Professor Jennifer Doudna, who will be a member of the LGR's steering committee.